Stocks Health care BRVE
NASDAQ · Health careBraveheart Bio, Inc. (BRVE)
At June 30, 2026 it held $122.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on September 8, 2026.
Key facts about Braveheart Bio, Inc.
- Net worth
- Braveheart Bio, Inc. has a market value (market cap) of $1.4B at the latest share price. A company's "net worth" usually means this market value or the shareholders' equity on its balance sheet.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on September 8, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
What Braveheart Bio, Inc. does
Braveheart Bio, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BRVE.
Earnings: every quarter and the next report date
Latest SEC filings
What Braveheart Bio, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Passive stake (5% or more) SCHEDULE 13G
- November 6, 2026
- November 5, 2026Passive stake (5% or more) SCHEDULE 13G
- September 10, 2026Activist stake changed SCHEDULE 13D/A
- September 8, 2026
- September 8, 2026
- August 18, 2026Activist stake (5% or more) SCHEDULE 13D
- August 14, 2026Activist stake (5% or more) SCHEDULE 13D
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 7, 2026
Insider trades
What the people running Braveheart Bio, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 7, 2026 | Orbimed Advisors LLCDirector, 10% owner | Exercised optionsindirect | 9,132,420 | - |
| August 7, 2026 | Orbimed Advisors LLCDirector, 10% owner | Boughtindirect | 1,666,667 | $30M |
| August 7, 2026 | Orbimed Advisors LLCDirector, 10% owner | Boughtindirect | 273,333 | $4.9M |
| August 7, 2026 | Chimovits ErezDirector, 10% owner | Exercised optionsindirect | 9,132,420 | - |
| August 7, 2026 | Chimovits ErezDirector, 10% owner | Boughtindirect | 1,666,667 | $30M |
| August 7, 2026 | Chimovits ErezDirector, 10% owner | Boughtindirect | 273,333 | $4.9M |
| August 7, 2026 | AH Bio Fund IV, L.P.10% owner | Exercised optionsindirect | 9,132,420 | - |
| August 7, 2026 | AH Bio Fund IV, L.P.10% owner | Boughtindirect | 1,100,000 | $19.8M |
Who owns BRVE
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Orbimed Advisors LLC13D, may seek influence with 2 related filers | 13.5% | September 10, 2026 |
| AH Bio Fund IV, L.P.13D, may seek influence with 3 related filers | 11.4% | August 14, 2026 |
| Fmr LLC13G, passive with 1 related filers | 8.2% | November 5, 2026 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd.13G, passive | 8.2% | November 9, 2026 |
| Frazier Life Sciences Public Fund, L.P.13G, passive with 8 related filers | 5.5% | August 14, 2026 |
Largest institutional holders
Insiders
11 insiders reported holding 45,017,878 shares in total, about $861.6M at the last price.
| Holder | Shares |
|---|---|
| Forbion Growth Opportunities Fund III Cooperatief U.A.10% owner | 21,826,02410,185,478 held indirectly |
| AH Bio Fund IV, L.P.10% owner | 10,232,42010,232,420 held indirectly |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd.10% owner | 7,420,091 |
| Murdoch TravisCEO and President, Director | 2,940,670 |
| Viehbacher ChristopherDirector | 609,519 |
| Malek David IDirector | 533,845 |
| Rickey James PaulChief Financial Officer | 520,927 |
| Anderson Michele A.Chief Development Officer | 332,161 |
| Chimovits ErezDirector, 10% owner | 273,333273,333 held indirectly |
| Orbimed Advisors LLCDirector, 10% owner | 273,333273,333 held indirectly |
Questions about BRVE
What does Braveheart Bio, Inc. do?
Braveheart Bio, Inc. is a company in the Health care sector, listed on NASDAQ as BRVE. Its shares trade on NASDAQ under the ticker BRVE.
What is Braveheart Bio, Inc.'s net worth?
Braveheart Bio, Inc. has a market value (market cap) of $1.4B at the latest share price. A company's "net worth" usually means this market value or the shareholders' equity on its balance sheet.
When did Braveheart Bio, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on September 8, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake (5% or more) from November 9, 2026.
Similar companies
Compare BRVE with
Follow BRVE
Get an email when Braveheart Bio, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Braveheart Bio, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.